Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.
about
The evolution of poxvirus vaccinesDevelopment of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infectionCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxPrinciples of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agentsProspective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic reviewOrthopox Viruses: Infections in HumansSafety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+ effector/memory CD4+ lymphocytes in humans.How advances in immunology provide insight into improving vaccine efficacy.Evaluation of smallpox vaccines using variola neutralization.Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersIMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responsesVennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study populationVaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsBoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge.A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesSafety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.Therapeutic and prophylactic drugs to treat orthopoxvirus infectionsSafety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbitsImmunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination
P2860
Q26995905-1B0498D2-A37F-4A15-8E82-49CA10B38464Q27321985-509E1208-207F-487F-AA74-25B5E68D5F94Q27346933-2793A706-CA6B-4939-8CD9-D073E814C971Q28384852-64137443-272A-43AE-B278-337533554A1DQ28485174-6E5F1127-30C4-4B05-922D-3A4BD834324BQ28742218-E56FFE3F-B770-48B8-9077-36561912C22DQ30151079-2164A43C-D83D-4CCE-9887-8B9D3A4CEEB6Q30375979-D4212380-DB86-4AB0-9EE2-59FCDE8D5062Q33624420-D01CB00D-529F-4099-ACFC-722021E2B400Q33770909-856669F5-8741-47B1-9C1A-6D799DECC038Q33815680-778BC0B9-F473-4DCD-9976-0CB62A27B15AQ33896995-71E13A95-AF28-428B-BF47-18B601B2EAFEQ33920540-503BF662-6147-4083-9A14-66A760F01682Q33930815-8C3E78DF-6E39-4B32-8A47-30A5FAE100D9Q34470311-E7B77920-16AE-47CE-9894-23B3578030F4Q34502997-DC8AB0EA-2DE4-4CDA-9951-E70883711FBCQ34589611-C6C9D995-2972-418A-828D-94ACF8F98E74Q34907430-657D4FF5-D0B6-44F3-9F37-42E8936DC501Q34952043-5E2C2CF4-D047-4AFA-8B4E-D8712EC183D5Q35089019-D2AEA9CC-F92B-4E36-8CFC-E3A3B2313689Q35140284-D54B0D6B-F087-4CF4-A83B-4599B2CFC3C3Q35447516-1687F27C-CE4C-4D0D-8670-62D252C58469Q35571248-F6AE44D1-12BE-40FE-8CD8-CF12380DE8DEQ35634159-E4F9ABC9-03FF-4C78-B223-9DABAFC3AF9AQ35667240-3CC48D30-C294-4570-A5D2-6B13E8A0573DQ35800226-85DBE99F-3B24-4652-A8B0-602AC62F3A56Q35826728-926BB82D-2B0C-4817-923F-F09B151A913EQ36057928-CA831221-C61D-48A6-AB36-62154BE10A3CQ36086257-AD20312E-AFC9-41EB-9471-E5795F413DC0Q36424513-3212DEFB-8008-461E-9EC7-603220C583F8Q36593175-98F4FEA7-63E6-427D-8F41-154503C73084Q36668517-E001DE52-C163-4455-A330-7DB494E82FB3Q36727280-DB70E209-25F2-4371-A5CE-3E5BCD4CBFD5Q36846282-8E2D6456-B022-48A5-AB5D-66990A2D7D98Q36978610-C1F09552-563E-4E2C-8EBA-2D5BE91DB77AQ37009973-975CA8D7-4149-4A37-AC01-0B2BAA4086DAQ37127399-BAD9EBF8-5615-430D-BBA6-AA52662F6A85Q37135398-46EB2CE6-E51C-4C49-8202-A5B151255FFEQ37174356-E5DD322C-108C-4291-B94E-38B259B3B5C4Q37183807-7AF21D74-D4DC-4351-89D0-DEF60D6326EC
P2860
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical and immunologic respo ...... followed by Dryvax challenge.
@en
Clinical and immunologic responses to multiple doses of IMVAMUNE
@nl
type
label
Clinical and immunologic respo ...... followed by Dryvax challenge.
@en
Clinical and immunologic responses to multiple doses of IMVAMUNE
@nl
prefLabel
Clinical and immunologic respo ...... followed by Dryvax challenge.
@en
Clinical and immunologic responses to multiple doses of IMVAMUNE
@nl
P2093
P2860
P1433
P1476
Clinical and immunologic respo ...... followed by Dryvax challenge.
@en
P2093
Bernard R Chaitman
Frances K Newman
Francis A Ennis
Heather Hill
Jeffrey S Kennedy
Jens Vollmar
Lihan K Yan
Paul Chaplin
Sharon E Frey
Vera Sobek
P2860
P304
P356
10.1016/J.VACCINE.2007.10.017
P407
P577
2007-10-26T00:00:00Z